Qualigen Therapeutics Sees 96% Stock Surge Amid New Developments

QUALIGEN THERAPEUTICS INC: COMPANY PROFILE AND RECENT DEVELOPMENTS

Qualigen Therapeutics, Inc. (Nasdaq: QLGN) is a clinical-stage biotechnology company headquartered in Carlsbad, California. The company focuses on developing treatments for adult and pediatric cancers, with three investigational oncology programs in its research pipeline: QN-302, a small molecule selective transcription inhibitor; a family of Pan-RAS protein-protein interaction inhibitors; and QN-247.

Corporate Structure

Qualigen Therapeutics employs between 11 and 50 professionals, as indicated by its LinkedIn profile. As a public company listed on the Nasdaq exchange under the ticker QLGN, Qualigen maintains an organizational structure that spans research, clinical operations, regulatory affairs, and business development.

Oncology by National Cancer Institute

Recent Developments and News

• On May 19, 2025, Qualigen filed a Form 8-K with the U.S. Securities and Exchange Commission (SEC) reporting changes in shareholders’ equity (Item 3.01), regulatory disclosures under Regulation FD (Item 7.01), and results of operations and financial condition (Item 9.01).
• On June 24, 2025, the company submitted another 8-K under Item 5.02 to disclose a change in its executive management team.
• On June 30, 2025, Qualigen filed its Annual Report on Form 10-K for the fiscal year ended March 31, 2025, summarizing pipeline progress, risk factors, and strategic initiatives.
• On July 16, 2025, QLGN shares closed at $6.9336 on the Nasdaq, reflecting a 96.42% change from the prior trading day, on a volume of 7,597,676 shares.

In July 2023, Qualigen completed the sale of its FastPack® diagnostics business to Chembio Diagnostics, Inc., a subsidiary of BIOSYNEX Group, to concentrate resources on its oncology pipeline.

Financial and Strategic Analysis

On July 16, 2025, Qualigen’s stock price of $6.9336 indicated a 96.42% change and pointed to elevated trading activity. The share price has fluctuated within a 52-week range of $2.85 (April 11, 2025) to $19.00 (July 16, 2024). Public data indicate a market capitalization of approximately $5.8 million, 1.64 million shares outstanding, and a 10-day average volume of about 20,000 shares, figures representative of a small-cap clinical-stage biotech.

Qualigen’s pipeline targets mechanisms with applicability to numerous cancers. QN-302 is designed to bind G-quadruplex structures in cancer cells to inhibit proliferation. The Pan-RAS inhibitor program aims to block mutated RAS proteins from interacting with effector partners, potentially affecting up to 25% of all cancers, including certain pancreatic, colorectal, and lung malignancies. QN-247 is currently under investigation. The company also notes potential opportunities for Orphan Drug Designation for its lead candidates.

Market Position and Industry Context

Qualigen operates within the biotechnology research sector, where many clinical-stage companies seek regulatory approvals and partnerships. The company differentiates itself through its specialized oncology programs and potential orphan indications. The divestiture of its diagnostics segment in 2023 reflects a focused strategy on therapeutics. Qualigen actively seeks licensing and collaboration opportunities to advance its development programs and secure funding for clinical trials.

tl;dr

On July 16, 2025, QLGN shares changed 96.42% to $6.9336 on Nasdaq with 7.6 million shares traded. This followed Qualigen’s Form 10-K filing on June 30, 2025, and an 8-K on June 24, 2025, disclosing management changes. The company is advancing three oncology candidates—QN-302, Pan-RAS inhibitors, and QN-247—and continues to pursue collaborations and orphan drug pathways for its clinical-stage programs.